| Certificate of Mailing | |
|--|--|
| Date of DepositFebruary 7, 2002 | Label Number: EL509047750US |
| I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231. Guy Beardsley Guy Beardsley | |
| Printed name of person mailing correspondence | Signature of person mailing correspondence |

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Richard A. Goldsby et al.

Art Unit:

Not Yet Assigned

Serial No.:

Not Yet Assigned

Examiner:

Not Yet Assigned

Filed:

February 7, 2002

Customer No.:

21559

Title:

PRODUCTION OF UNGULATES, PREFERABLY BOVINES THAT

PRODUCE HUMAN IMMUNOGLOBULINS

Box Patent Application Assistant Commissioner For Patents Washington, DC 20231

PRELIMINARY AMENDMENT

Prior to examination of the above-referenced application, please consider the following amendment and remarks. Please amend the application as follows.

In the Specification:

Please insert the following new paragraph before the first paragraph on page 1 of the specification.

Cross-Reference to Related Application

This application is a divisional of U.S. Provisional Application No. 09/714,185, filed November 17, 2000, which claims priority from U.S. Provisional Application No. 60/166,410, filed November 19, 1999.

Please replace the paragraph on page 9, lines 21 to 26, with the following paragraph that has been re-written in clean form.

Figure 1. This figure contains a schematic of a targeting construct used for effecting inactivation of the rag-2 gene (SEQ ID NO. 1). In the Figure: the organization of the endogenous rag-2 gene is shown with an arrow representing the direction of transcription; and the targeting construct maintains the sequences 5' and 3' of the rag-2 coding region and the coding region is disrupted with a neomycin gene in the opposite transcriptional orientation.

Kindly insert the enclosed sequence listing at the end of the application.

REMARKS

The specification has been amended to provide a unique sequence identification number for the polynucleotide sequence within the specification. The attached sequence listing has also been inserted into the application. No new matter is introduced by the amendment.

Respectfully submitted,

Date: 7 Februay 2002

Karen L. Elbing, Ph.D

Reg. No. 35,238

Clark & Elbing LLP 176 Federal Street Boston, MA 02110

Telephone: 617-428-0200

Facsimile: 617-428-7045

F:\50195\50195.009003 Preliminary Amendment.wpd

21559 PATENT TRADEMARK OFFIC

| Certificate of Mailing | |
|---|---|
| Date of DepositFebruary 7, 2002 | Label Number: EL509047750US |
| I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231. Guy Beardsley | |
| Printed name of person mailing correspondence | Signature of person maliting correspondence |

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Richard A. Goldsby et al.

Art Unit:

Not Yet Assigned

Serial No.:

Not Yet Assigned

Examiner:

Not Yet Assigned

Filed:

February 7, 2002

Customer No.:

21559

Title:

PRODUCTION OF UNGULATES, PREFERABLY BOVINES THAT

PRODUCE HUMAN IMMUNOGLOBULINS

Box Patent Application Assistant Commissioner For Patents Washington, DC 20231

Version with Markings to Show Changes Made

The new paragraph inserted before the first paragraph on page 1 of the specification is presented below.

Cross-Reference to Related Application

This application is a divisional of U.S. Provisional Application No. 09/714,185, filed November 17, 2000, which claims priority from U.S. Provisional Application No. 60/166,410, filed November 19, 1999.

A marked-up version of the paragraph on page 9, lines 21 to 26, of the specification is presented below.

"Figure 1. This figure contains a schematic of a targetting construct used for effecting inactivation of the rag-2 gene (SEQ ID NO. 1). In the Figure: the organization of the endogenous rag-2 gene is shown with an arrow representing the direction of transcription; and the targeting construct maintains the seuques 5' and 3' of the rag-2 coding region and the coding region is disrupted with a neomycin gene in the opposite transcriptional orientation."

50195.009003 Preliminary Amendment - Microsoft Word